These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 26242857)

  • 1. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab.
    Čarija A; Ivić I; Marasović-Krstulović D; Puizina-Ivić N
    Rheumatology (Oxford); 2015 Nov; 54(11):2114-6. PubMed ID: 26242857
    [No Abstract]   [Full Text] [Related]  

  • 2. Morphea in patients with psoriasis treated with ustekinumab: a scoping review.
    Metko D; Mehta S; Vender R
    Arch Dermatol Res; 2024 Jul; 316(8):492. PubMed ID: 39066922
    [No Abstract]   [Full Text] [Related]  

  • 3. Morphea-like lesions after treatment with ustekinumab.
    Shaffer BR; Zaino M; Bowers NL; Hunter D; Feldman SR
    Dermatol Online J; 2024 Jun; 30(3):. PubMed ID: 39090052
    [No Abstract]   [Full Text] [Related]  

  • 4. In brief: Wezlana - an ustekinumab biosimilar interchangeable with Stelara.
    Med Lett Drugs Ther; 2024 Jul; 66(1707):119. PubMed ID: 39008107
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative study of paradoxical and classical psoriasis: what are clinical and therapeutic differences?
    Demir Y; Ak T; Temiz SNY; Engin B
    Arch Dermatol Res; 2024 May; 316(6):216. PubMed ID: 38787400
    [No Abstract]   [Full Text] [Related]  

  • 6. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.
    Landells I; Marano C; Hsu MC; Li S; Zhu Y; Eichenfield LF; Hoeger PH; Menter A; Paller AS; Taieb A; Philipp S; Szapary P; Randazzo B
    J Am Acad Dermatol; 2015 Oct; 73(4):594-603. PubMed ID: 26259989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin.
    D'Amico F; Trovato C; Skarmoutsou E; Rossi GA; Granata M; Longo V; Gangemi P; Pettinato M; Mazzarino MC
    J Dermatol Sci; 2015 Oct; 80(1):38-44. PubMed ID: 26276441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study.
    Napolitano M; Balato N; Caso F; Costa L; Megna M; Cirillo T; Balato A; Scarpa R
    Clin Exp Rheumatol; 2017; 35(1):137-140. PubMed ID: 27749221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
    Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
    Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of paradoxical eczematous eruption in psoriasis treated with secukinumab: A case report.
    Xiao Y; Peng S; Li X; Mao T; Fang M; Hu Y; Ye W
    Medicine (Baltimore); 2023 Feb; 102(6):e32844. PubMed ID: 36820537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching biologics in psoriasis - practical guidance and evidence to support.
    Tsai YC; Tsai TF
    Expert Rev Clin Pharmacol; 2020 May; 13(5):493-503. PubMed ID: 32394765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature.
    Caldarola G; Pirro F; Di Stefani A; Talamonti M; Galluzzo M; D'Adamio S; Magnano M; Bernardini N; Malagoli P; Bardazzi F; Potenza C; Bianchi L; Peris K; De Simone C
    Expert Opin Biol Ther; 2020 Jun; 20(6):665-672. PubMed ID: 32045273
    [No Abstract]   [Full Text] [Related]  

  • 13. Secukinumab-induced paradoxical hidradenitis suppurativa.
    Navarro-Triviño FJ; Sanchez-Parera R; Ruiz-Villaverde R
    Dermatol Ther; 2020 Jan; 33(1):e13150. PubMed ID: 31670893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition.
    Napolitano M; Megna M; Fabbrocini G; Nisticò SP; Balato N; Dastoli S; Patruno C
    Br J Dermatol; 2019 Sep; 181(3):604-606. PubMed ID: 30768788
    [No Abstract]   [Full Text] [Related]  

  • 15. Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature.
    Munera-Campos M; Ballesca F; Carrascosa JM
    Actas Dermosifiliogr (Engl Ed); 2018 Nov; 109(9):791-800. PubMed ID: 29903464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others.
    Puig L
    Curr Probl Dermatol; 2018; 53():49-63. PubMed ID: 29131037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New onset or transition of disease state of psoriatic arthritis during treatment with ustekinumab: A single-center retrospective study.
    Asahina A; Umezawa Y; Momose M; Honda H; Yanaba K; Nakagawa H
    J Dermatol; 2017 Dec; 44(12):1380-1384. PubMed ID: 28771778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug- or Vaccine-Induced/Aggravated Psoriatic Arthritis: A Systematic Review.
    Yeh YT; Tsai TF
    Dermatol Ther (Heidelb); 2024 Jan; 14(1):59-81. PubMed ID: 38183617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study.
    Oguz Topal I; Baysak S; Altunay İK; Kara Polat A; Arıkan EE; Özkur E; Aytekin S; Dogan B; Özkök Akbulut T; Topaloğlu Demir F; Karadağ AS
    An Bras Dermatol; 2022; 97(5):566-574. PubMed ID: 35843765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Systematic Review Characterizing Psoriatic Arthritis Onset and Exacerbation in Patients Receiving Biologic Therapy.
    Sachdeva M; Abduelmula A; Mufti A; Georgakopoulos JR; Lytvyn Y; Yeung J
    J Cutan Med Surg; 2022; 26(4):414-419. PubMed ID: 35317662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.